Use of zoledronic acid in antiosteoporosis treatment is associated with a decreased blood lipid level in postmenopausal women with osteoporosis: a cohort study in China.

This cohort study found that ZA might exert a protective effect on lipid metabolism in postmenopausal women with osteoporosis. In postmenopausal women with lipid disorders suffering from osteoporosis, the treatment with ZA combined with atorvastatin significantly reduced the level of blood lipid compared with atorvastatin alone.